GlassScriptPhysician profile
Caroline A Spettel
NPI 1144470998
$378.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $379.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $78.84 | 2021 | |
| Vanda Pharmaceuticals INC. | $52.64 | 2021 | |
| Amarin Pharma, INC. | $52.61 | 2021 | |
| Lilly USA, LLC | $28.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.66 | 2021 | |
| Glaxosmithkline, LLC. | $25.18 | 2021 | |
| Novo Nordisk INC | $23.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.25 | 2021 | |
| Merck Sharp & Dohme LLC | $18.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.27 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Spettel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.